Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of GR1802 injection plus background therapy in seasonal allergic rhinitis
CTR20240601Phase 2Completed
- Sponsor
- Zhixiang Jintai
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of telikibart in seasonal allergic rhinitis (SAR), sponsored by Zhixiang Jintai. Started Mar 2024; status: completed.
02
Drugs
telikibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20240601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240601.